<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837744</url>
  </required_header>
  <id_info>
    <org_study_id>ABPL/002</org_study_id>
    <secondary_id>U1111-1185-5780</secondary_id>
    <secondary_id>CTRI/2016/07/007115</secondary_id>
    <nct_id>NCT02837744</nct_id>
  </id_info>
  <brief_title>Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure</brief_title>
  <acronym>AHD</acronym>
  <official_title>Safety and Efficacy of Axiostat® Hemostatic Dressing on Radial Access After Percutaneous Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axio Biosolutions Pvt. Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axio Biosolutions Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate Safety and Efficacy of Axiostat® hemostatic dressing in terms of time to achieve
      hemostasis, post application complication and comfort levels of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate Safety and Efficacy of Axiostat® hemostatic dressing in terms of time to achieve
      hemostasis, post application complication and comfort levels of patients who have undergone
      radial intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to achieve hemostasis</measure>
    <time_frame>1 Day</time_frame>
    <description>Time to achieve hemostasis by observing the time at which blood oozing through or from periphery of the dressing stops.
Unit of measurement is minutes:seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with hemostasis;number of patients with rebleeding</measure>
    <time_frame>1 Day</time_frame>
    <description>Number of patients will be counted (unit of measurement is number/count of patients)
Number of patients with hemostasis
Number of patients with rebleeding after removal of Axiostat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantity of Product used</measure>
    <time_frame>1 Day</time_frame>
    <description>Number of Axiostat® required to achieve hemostasis. Unit of measurement is number.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Irritation &amp; &amp; Formation of Hematoma</measure>
    <time_frame>Upto 2 Days</time_frame>
    <description>(1)Observing Allergy/Skin Irritation (2))Observation of formation of Hematoma and/or any vascular complication after removal of Axiostat®.
Mode of Measurement is Visual Observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of use of Product &amp; Patient Comfort Level</measure>
    <time_frame>Upto 2 Days</time_frame>
    <description>Patients comfort level as assessed by verbal inquiry after completion of procedure.
Level of ease of use of product. Mode of Measurement is Verbal Inquiry.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Angiography</condition>
  <condition>Angioplasty</condition>
  <arm_group>
    <arm_group_label>Axiostat®</arm_group_label>
    <description>Size: 3.5 cm X 3.5 cm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Axiostat®</intervention_name>
    <description>Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.</description>
    <arm_group_label>Axiostat®</arm_group_label>
    <other_name>Hemostatic Dressing</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients who came to the institution/hospital and provided informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18 years.

          2. Patient and/or patient's legal representative and/or impartial witness has/have been
             informed of the nature of the study and agrees to its provision and has provided
             written informed consent as approved by the Ethics Committee of the investigative
             site.

          3. Iatrogenic puncture

          4. Patient who want to undergo radial intervention.

          5. All puncture size must be less than 2.5cm.

        Exclusion Criteria:

          1. Prior diagnosis of disease or medical condition affecting the ability of blood to clot
             (e.g., hemophilia.).

          2. Patients with known sensitivity to chitosan (shellfish) used in this study.

          3. Patients who, in the opinion of the Investigator, may not complete the study for any
             reason, e.g. Patient requiring Immediate suturing.

          4. Patient is currently participating in an investigational drug or dressing study that
             has not yet completed its primary endpoint interferes with procedure and assessments
             in this trial.

          5. Pregnant women.

          6. Patients with hemorrhagic shock.

          7. Patient having hemoglobin &lt; 9 g/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Chag, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Care Institute of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Care Institute of Medical Sciences,Nr. Shukan Mall, Off Science City Road,Sola</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

